Veradermics' Oral Hair-Loss Pill Deepens Hair Count at 12 Months in Phase 3 Study
MANE has more than doubled off its 52-week low of $32.
Summary
Veradermics reported positive 12-month topline data from Part B of Study '302', the registration-directed Phase 2/3 trial of oral extended-release minoxidil VDPHL01 in 519 men with pattern hair loss. Non-vellus target-area hair count rose 43.9 hairs/cm2 in the twice-daily arm and 29.7 hairs/cm2 in the once-daily arm from baseline to Month 12, with the BID dose still deepening and the QD dose holding its gain. At Month 12, 89.1% of BID and 79.8% of QD patients reported visible improvement in hair coverage on the AAIRS, and investigators graded 92.2% and 74.4% as improved. No treatment-related serious adverse events, no cardiac adverse events of special interest and no new safety signals appeared through Month 12. This follows the October 19 release of positive Study '304' Phase 3 results and completes the planned placebo-controlled male data set, leaving the female Study '306' readout in the first half of 2027 as the next clinical milestone. The company is hosting a call at 8:00 a.m. ET today to walk through the data.
At the time of this announcement, MANE was trading at $142.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $32.00 to $146.58. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.